3-V Biosciences Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:3-V Biosciences Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10845
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:18
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
3-V Biosciences Inc (3-V Biosciences) is a clinical-stage pharmaceutical company that develops novel therapeutics in metabolic diseases. The company offers TVB-2640, a fatty acid synthase inhibitor used for the treatment of solid tumors, including non-small cell lung cancer (NSCLC), breast cancer, and ovarian cancer. Its pipeline program include fatty acid synthase inhibitor amd research platform in the treatment of solid tumors. 3-V Biosciences provides FASN inhibitor, an essential enzyme which is responsible for the synthesis of palmitic acid and used in tumor metabolism, tumor cell survival and lipid signaling. The company develops antiviral therapeutic candidates for respiratory syncytial virus, cytomegalovirus, and other human pathogens. 3-V Biosciences is headquartered in Menlo Park, California, the US.

3-V Biosciences Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
3-V Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
3-V Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
3-V Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
3-V Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
3-V Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
3-V Biosciences Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
3-V Biosciences Raises USD28.5 Million in Series D Financing 10
3-V Biosciences Raises US$20 Million In Series C Financing 12
3-V Biosciences Secures USD8.09 Million in Venture Funding 13
3-V Biosciences Secures US$20 Million In Venture Financing 14
3-V Biosciences Inc – Key Competitors 15
3-V Biosciences Inc – Key Employees 16
3-V Biosciences Inc – Locations And Subsidiaries 17
Head Office 17
Appendix 18
Methodology 18
About GlobalData 18
Contact Us 18
Disclaimer 18

List of Tables
3-V Biosciences Inc, Pharmaceuticals & Healthcare, Key Facts 2
3-V Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
3-V Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
3-V Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
3-V Biosciences Inc, Deals By Therapy Area, 2012 to YTD 2018 8
3-V Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
3-V Biosciences Raises USD28.5 Million in Series D Financing 10
3-V Biosciences Raises US$20 Million In Series C Financing 12
3-V Biosciences Secures USD8.09 Million in Venture Funding 13
3-V Biosciences Secures US$20 Million In Venture Financing 14
3-V Biosciences Inc, Key Competitors 15
3-V Biosciences Inc, Key Employees 16

List of Figures
3-V Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
3-V Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
3-V Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
3-V Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
3-V Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
3-V Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
3-V Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
3-V Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[3-V Biosciences Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Viad Corp:企業の戦略・SWOT・財務情報
    Viad Corp - Strategy, SWOT and Corporate Finance Report Summary Viad Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Taejoon Pharm Co Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Taejoon Pharm Co Ltd (Taejoon) is a pharmaceutical company that markets ophthalmic agents and other drugs. The company offers injections, powders, eye drops, spray, syrups, tablets, soft capsules, liquids for external use, and hard capsules. Its powder products comprise coolprep powder, taej …
  • China National Chemical Corp:石油・ガス:M&Aディール及び事業提携情報
    Summary China National Chemical Corp (ChemChina) is a state-owned enterprise that develops and markets chemicals. The company offers chemical materials and specialty chemicals, agrochemicals, oil processing and refining products, basic chemicals, and rubber products. ChemChina also manufactures equi …
  • Samart Corporation Plc (SAMART):企業の財務・戦略的SWOT分析
    Samart Corporation Plc (SAMART) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Alnylam Pharmaceuticals Inc (ALNY):製薬・医療:M&Aディール及び事業提携情報
    Summary Alnylam Pharmaceuticals Inc (Alnylam) is a biopharmaceutical company which discovers, develops and commercializes therapeutics based on Ribo Nucleic Acid interference (RNAi). The company offers a broad pipeline of investigational RNAi therapeutics in the areas of genetic medicines, hepatic i …
  • Daily Mail and General Trust plc:企業のM&A・事業提携・投資動向
    Daily Mail and General Trust plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Daily Mail and General Trust plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on merge …
  • DiaCarta Inc:医療機器:M&Aディール及び事業提携情報
    Summary DiaCarta Inc (DiaCarta) is a developer of molecular diagnostics products for cancer and infectious diseases. The company offers genomic testing for biomarkers and also provides clinical sample testing services in their CLIA-certified lab. It offers products such as gene mutation detection ki …
  • Petrel Resources Plc (PET):企業の財務・戦略的SWOT分析
    Summary Petrel Resources Plc (Petrel Resources) is an oil and gas company that provides exploration and production of crude oil and natural gas across Iraq. The company provides areas of operations such as Luhais and Subba in Southern Iraq, Tano Basin in Ghana, Porcupine Basin in Ireland, and others …
  • O’Reilly Automotive, Inc.:企業の戦略・SWOT・財務情報
    O'Reilly Automotive, Inc. - Strategy, SWOT and Corporate Finance Report Summary O'Reilly Automotive, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • WuXi NextCODE Genomics:医療機器:M&Aディール及び事業提携情報
    Summary WuXi NextCODE Genomics USA Inc (WuXi NextCODE), a subsidiary of Wuxi Pharmatech (Cayman) Inc, is a genomic information company that offers competencies in generating, organizing, mining, sharing and applying genomic data. The company develops gene sequence analysis platform and database arch …
  • Clarient Inc-医療機器分野:企業M&A・提携分析
    Summary Clarient Inc (Clarient) is a cancer diagnostic laboratory services provider that provides comprehensive cancer–diagnostic laboratory services. The company provides oncology testing and other diagnostics services. Clarient offers detailed information to characterize and assess cancer for accu …
  • IDOX Plc (IDOX):企業の財務・戦略的SWOT分析
    Summary IDOX Plc (IDOX) is an information technology company that supplies and develops software solutions and information services. The company offers services such as funding, manages services, government and compliance solutions. Its government services include environmental, legal, democratic, e …
  • Essilor International Compagnie Generale d’Optique SA (EI):企業の財務・戦略的SWOT分析
    Essilor International Compagnie Generale d'Optique SA (EI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the compa …
  • Magellan Diagnostics Inc-医療機器分野:企業M&A・提携分析
    Summary Magellan Diagnostics Inc (Magellan Diagnostics), formerly ESA Inc, a subsidiary of Meridian Bioscience Inc, is a medical device company that provides point-of-care systems, clinical laboratory instruments, and analytical laboratory services. The company’s products include LeadCare II, LeadCa …
  • Pretium Packaging, L.L.C.:企業の戦略・SWOT・財務分析
    Pretium Packaging, L.L.C. - Strategy, SWOT and Corporate Finance Report Summary Pretium Packaging, L.L.C. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Multan Electric Power Co Ltd:企業の戦略的SWOT分析
    Multan Electric Power Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Vattenfall AB.:企業の戦略・SWOT・財務分析
    Vattenfall AB. - Strategy, SWOT and Corporate Finance Report Summary Vattenfall AB. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Parsons Corporation:企業の戦略・SWOT・財務分析
    Parsons Corporation - Strategy, SWOT and Corporate Finance Report Summary Parsons Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • JCR Pharmaceuticals Co Ltd (4552):製薬・医療:M&Aディール及び事業提携情報
    Summary JCR Pharmaceuticals Co Ltd (JCR) manufactures, sells, buys, imports and exports pharmaceutical products. It provides biopharmaceuticals in the field of regenerative medicine for the treatment of rare diseases. The company offers pharmaceuticals to treat growth hormone deficiency, turner synd …
  • Euronet Worldwide, Inc.:企業の戦略・SWOT・財務分析
    Euronet Worldwide, Inc. - Strategy, SWOT and Corporate Finance Report Summary Euronet Worldwide, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆